 | • レポートコード：MRC2-11QY08780 • 出版社/出版日：QYResearch / 2020年11月25日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料はPCSK9阻害剤のグローバル市場について調査・分析したレポートです。種類別（エパサ（エボロクマブ）、プラリューエント（アリロクマブ）、ボコシズマブ、その他）市場規模、用途別（臨床応用、医薬品開発、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別PCSK9阻害剤の競争状況、市場シェア ・世界のPCSK9阻害剤市場：種類別市場規模 2015年-2020年（エパサ（エボロクマブ）、プラリューエント（アリロクマブ）、ボコシズマブ、その他） ・世界のPCSK9阻害剤市場：種類別市場規模予測 2021年-2026年（エパサ（エボロクマブ）、プラリューエント（アリロクマブ）、ボコシズマブ、その他） ・世界のPCSK9阻害剤市場：用途別市場規模 2015年-2020年（臨床応用、医薬品開発、その他） ・世界のPCSK9阻害剤市場：用途別市場規模予測 2021年-2026年（臨床応用、医薬品開発、その他） ・北米のPCSK9阻害剤市場分析：米国、カナダ ・ヨーロッパのPCSK9阻害剤市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアのPCSK9阻害剤市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米のPCSK9阻害剤市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカのPCSK9阻害剤市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：Amgen、Eli Lilly、Sanofi、Pfizer、Novartis、Roche、Merck、Alnylam、AstraZeneca、Affiris、BMS、Ionis Pharmaceuticals、Cyon Therapeutics、Daiichi Sankyo ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global PCSK9 Inhibitors Market
The global PCSK9 Inhibitors market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global PCSK9 Inhibitors Scope and Market Size
PCSK9 Inhibitors market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global PCSK9 Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the PCSK9 Inhibitors market is segmented into
Epatha（Evolocumab）
Praluent（Alirocumab）
Bococizumab
Others
Segment by Application, the PCSK9 Inhibitors market is segmented into
Clinical Application
Drug Development
Other
Regional and Country-level Analysis
The PCSK9 Inhibitors market is analysed and market size information is provided by regions (countries).
The key regions covered in the PCSK9 Inhibitors market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and PCSK9 Inhibitors Market Share Analysis
PCSK9 Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in PCSK9 Inhibitors business, the date to enter into the PCSK9 Inhibitors market, PCSK9 Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Amgen
Eli Lilly
Sanofi
Pfizer
Novartis
Roche
Merck
Alnylam
AstraZeneca
Affiris
BMS
Ionis Pharmaceuticals
Cyon Therapeutics
Daiichi Sankyo
1 Study Coverage
1.1 PCSK9 Inhibitors Product Introduction
1.2 Market Segments
1.3 Key PCSK9 Inhibitors Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global PCSK9 Inhibitors Market Size Growth Rate by Type
1.4.2 Epatha（Evolocumab）
1.4.3 Praluent（Alirocumab）
1.4.4 Bococizumab
1.4.5 Others
1.5 Market by Application
1.5.1 Global PCSK9 Inhibitors Market Size Growth Rate by Application
1.5.2 Clinical Application
1.5.3 Drug Development
1.5.4 Other
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global PCSK9 Inhibitors Market Size, Estimates and Forecasts
2.1.1 Global PCSK9 Inhibitors Revenue 2015-2026
2.1.2 Global PCSK9 Inhibitors Sales 2015-2026
2.2 Global PCSK9 Inhibitors, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global PCSK9 Inhibitors Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global PCSK9 Inhibitors Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global PCSK9 Inhibitors Competitor Landscape by Players
3.1 PCSK9 Inhibitors Sales by Manufacturers
3.1.1 PCSK9 Inhibitors Sales by Manufacturers (2015-2020)
3.1.2 PCSK9 Inhibitors Sales Market Share by Manufacturers (2015-2020)
3.2 PCSK9 Inhibitors Revenue by Manufacturers
3.2.1 PCSK9 Inhibitors Revenue by Manufacturers (2015-2020)
3.2.2 PCSK9 Inhibitors Revenue Share by Manufacturers (2015-2020)
3.2.3 Global PCSK9 Inhibitors Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by PCSK9 Inhibitors Revenue in 2019
3.2.5 Global PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 PCSK9 Inhibitors Price by Manufacturers
3.4 PCSK9 Inhibitors Manufacturing Base Distribution, Product Types
3.4.1 PCSK9 Inhibitors Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers PCSK9 Inhibitors Product Type
3.4.3 Date of International Manufacturers Enter into PCSK9 Inhibitors Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global PCSK9 Inhibitors Market Size by Type (2015-2020)
4.1.1 Global PCSK9 Inhibitors Sales by Type (2015-2020)
4.1.2 Global PCSK9 Inhibitors Revenue by Type (2015-2020)
4.1.3 PCSK9 Inhibitors Average Selling Price (ASP) by Type (2015-2026)
4.2 Global PCSK9 Inhibitors Market Size Forecast by Type (2021-2026)
4.2.1 Global PCSK9 Inhibitors Sales Forecast by Type (2021-2026)
4.2.2 Global PCSK9 Inhibitors Revenue Forecast by Type (2021-2026)
4.2.3 PCSK9 Inhibitors Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global PCSK9 Inhibitors Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global PCSK9 Inhibitors Market Size by Application (2015-2020)
5.1.1 Global PCSK9 Inhibitors Sales by Application (2015-2020)
5.1.2 Global PCSK9 Inhibitors Revenue by Application (2015-2020)
5.1.3 PCSK9 Inhibitors Price by Application (2015-2020)
5.2 PCSK9 Inhibitors Market Size Forecast by Application (2021-2026)
5.2.1 Global PCSK9 Inhibitors Sales Forecast by Application (2021-2026)
5.2.2 Global PCSK9 Inhibitors Revenue Forecast by Application (2021-2026)
5.2.3 Global PCSK9 Inhibitors Price Forecast by Application (2021-2026)
6 North America
6.1 North America PCSK9 Inhibitors by Country
6.1.1 North America PCSK9 Inhibitors Sales by Country
6.1.2 North America PCSK9 Inhibitors Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America PCSK9 Inhibitors Market Facts & Figures by Type
6.3 North America PCSK9 Inhibitors Market Facts & Figures by Application
7 Europe
7.1 Europe PCSK9 Inhibitors by Country
7.1.1 Europe PCSK9 Inhibitors Sales by Country
7.1.2 Europe PCSK9 Inhibitors Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe PCSK9 Inhibitors Market Facts & Figures by Type
7.3 Europe PCSK9 Inhibitors Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific PCSK9 Inhibitors by Region
8.1.1 Asia Pacific PCSK9 Inhibitors Sales by Region
8.1.2 Asia Pacific PCSK9 Inhibitors Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific PCSK9 Inhibitors Market Facts & Figures by Type
8.3 Asia Pacific PCSK9 Inhibitors Market Facts & Figures by Application
9 Latin America
9.1 Latin America PCSK9 Inhibitors by Country
9.1.1 Latin America PCSK9 Inhibitors Sales by Country
9.1.2 Latin America PCSK9 Inhibitors Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America PCSK9 Inhibitors Market Facts & Figures by Type
9.3 Central & South America PCSK9 Inhibitors Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa PCSK9 Inhibitors by Country
10.1.1 Middle East and Africa PCSK9 Inhibitors Sales by Country
10.1.2 Middle East and Africa PCSK9 Inhibitors Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa PCSK9 Inhibitors Market Facts & Figures by Type
10.3 Middle East and Africa PCSK9 Inhibitors Market Facts & Figures by Application
11 Company Profiles
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen PCSK9 Inhibitors Products Offered
11.1.5 Amgen Related Developments
11.2 Eli Lilly
11.2.1 Eli Lilly Corporation Information
11.2.2 Eli Lilly Description and Business Overview
11.2.3 Eli Lilly Sales, Revenue and Gross Margin (2015-2020)
11.2.4 Eli Lilly PCSK9 Inhibitors Products Offered
11.2.5 Eli Lilly Related Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Description and Business Overview
11.3.3 Sanofi Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Sanofi PCSK9 Inhibitors Products Offered
11.3.5 Sanofi Related Developments
11.4 Pfizer
11.4.1 Pfizer Corporation Information
11.4.2 Pfizer Description and Business Overview
11.4.3 Pfizer Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Pfizer PCSK9 Inhibitors Products Offered
11.4.5 Pfizer Related Developments
11.5 Novartis
11.5.1 Novartis Corporation Information
11.5.2 Novartis Description and Business Overview
11.5.3 Novartis Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Novartis PCSK9 Inhibitors Products Offered
11.5.5 Novartis Related Developments
11.6 Roche
11.6.1 Roche Corporation Information
11.6.2 Roche Description and Business Overview
11.6.3 Roche Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Roche PCSK9 Inhibitors Products Offered
11.6.5 Roche Related Developments
11.7 Merck
11.7.1 Merck Corporation Information
11.7.2 Merck Description and Business Overview
11.7.3 Merck Sales, Revenue and Gross Margin (2015-2020)
11.7.4 Merck PCSK9 Inhibitors Products Offered
11.7.5 Merck Related Developments
11.8 Alnylam
11.8.1 Alnylam Corporation Information
11.8.2 Alnylam Description and Business Overview
11.8.3 Alnylam Sales, Revenue and Gross Margin (2015-2020)
11.8.4 Alnylam PCSK9 Inhibitors Products Offered
11.8.5 Alnylam Related Developments
11.9 AstraZeneca
11.9.1 AstraZeneca Corporation Information
11.9.2 AstraZeneca Description and Business Overview
11.9.3 AstraZeneca Sales, Revenue and Gross Margin (2015-2020)
11.9.4 AstraZeneca PCSK9 Inhibitors Products Offered
11.9.5 AstraZeneca Related Developments
11.10 Affiris
11.10.1 Affiris Corporation Information
11.10.2 Affiris Description and Business Overview
11.10.3 Affiris Sales, Revenue and Gross Margin (2015-2020)
11.10.4 Affiris PCSK9 Inhibitors Products Offered
11.10.5 Affiris Related Developments
11.1 Amgen
11.1.1 Amgen Corporation Information
11.1.2 Amgen Description and Business Overview
11.1.3 Amgen Sales, Revenue and Gross Margin (2015-2020)
11.1.4 Amgen PCSK9 Inhibitors Products Offered
11.1.5 Amgen Related Developments
11.12 Ionis Pharmaceuticals
11.12.1 Ionis Pharmaceuticals Corporation Information
11.12.2 Ionis Pharmaceuticals Description and Business Overview
11.12.3 Ionis Pharmaceuticals Sales, Revenue and Gross Margin (2015-2020)
11.12.4 Ionis Pharmaceuticals Products Offered
11.12.5 Ionis Pharmaceuticals Related Developments
11.13 Cyon Therapeutics
11.13.1 Cyon Therapeutics Corporation Information
11.13.2 Cyon Therapeutics Description and Business Overview
11.13.3 Cyon Therapeutics Sales, Revenue and Gross Margin (2015-2020)
11.13.4 Cyon Therapeutics Products Offered
11.13.5 Cyon Therapeutics Related Developments
11.14 Daiichi Sankyo
11.14.1 Daiichi Sankyo Corporation Information
11.14.2 Daiichi Sankyo Description and Business Overview
11.14.3 Daiichi Sankyo Sales, Revenue and Gross Margin (2015-2020)
11.14.4 Daiichi Sankyo Products Offered
11.14.5 Daiichi Sankyo Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 PCSK9 Inhibitors Market Estimates and Projections by Region
12.1.1 Global PCSK9 Inhibitors Sales Forecast by Regions 2021-2026
12.1.2 Global PCSK9 Inhibitors Revenue Forecast by Regions 2021-2026
12.2 North America PCSK9 Inhibitors Market Size Forecast (2021-2026)
12.2.1 North America: PCSK9 Inhibitors Sales Forecast (2021-2026)
12.2.2 North America: PCSK9 Inhibitors Revenue Forecast (2021-2026)
12.2.3 North America: PCSK9 Inhibitors Market Size Forecast by Country (2021-2026)
12.3 Europe PCSK9 Inhibitors Market Size Forecast (2021-2026)
12.3.1 Europe: PCSK9 Inhibitors Sales Forecast (2021-2026)
12.3.2 Europe: PCSK9 Inhibitors Revenue Forecast (2021-2026)
12.3.3 Europe: PCSK9 Inhibitors Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific PCSK9 Inhibitors Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: PCSK9 Inhibitors Sales Forecast (2021-2026)
12.4.2 Asia Pacific: PCSK9 Inhibitors Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: PCSK9 Inhibitors Market Size Forecast by Region (2021-2026)
12.5 Latin America PCSK9 Inhibitors Market Size Forecast (2021-2026)
12.5.1 Latin America: PCSK9 Inhibitors Sales Forecast (2021-2026)
12.5.2 Latin America: PCSK9 Inhibitors Revenue Forecast (2021-2026)
12.5.3 Latin America: PCSK9 Inhibitors Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa PCSK9 Inhibitors Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: PCSK9 Inhibitors Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: PCSK9 Inhibitors Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: PCSK9 Inhibitors Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key PCSK9 Inhibitors Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 PCSK9 Inhibitors Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. PCSK9 Inhibitors Market Segments
Table 2. Ranking of Global Top PCSK9 Inhibitors Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global PCSK9 Inhibitors Market Size Growth Rate by Type 2020-2026 (K Units) & (US$ Million)
Table 4. Major Manufacturers of Epatha（Evolocumab）
Table 5. Major Manufacturers of Praluent（Alirocumab）
Table 6. Major Manufacturers of Bococizumab
Table 7. Major Manufacturers of Others
Table 8. Global PCSK9 Inhibitors Market Size Growth Rate by Application 2020-2026 (K Units)
Table 9. Global PCSK9 Inhibitors Market Size by Region (K Units) & (US$ Million): 2020 VS 2026
Table 10. Global PCSK9 Inhibitors Sales by Regions 2015-2020 (K Units)
Table 11. Global PCSK9 Inhibitors Sales Market Share by Regions (2015-2020)
Table 12. Global PCSK9 Inhibitors Revenue by Regions 2015-2020 (US$ Million)
Table 13. Global PCSK9 Inhibitors Sales by Manufacturers (2015-2020) (K Units)
Table 14. Global PCSK9 Inhibitors Sales Share by Manufacturers (2015-2020)
Table 15. Global PCSK9 Inhibitors Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 16. Global PCSK9 Inhibitors by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in PCSK9 Inhibitors as of 2019)
Table 17. PCSK9 Inhibitors Revenue by Manufacturers (2015-2020) (US$ Million)
Table 18. PCSK9 Inhibitors Revenue Share by Manufacturers (2015-2020)
Table 19. Key Manufacturers PCSK9 Inhibitors Price (2015-2020) (USD/Unit)
Table 20. PCSK9 Inhibitors Manufacturers Manufacturing Base Distribution and Headquarters
Table 21. Manufacturers PCSK9 Inhibitors Product Type
Table 22. Date of International Manufacturers Enter into PCSK9 Inhibitors Market
Table 23. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 24. Global PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 25. Global PCSK9 Inhibitors Sales Share by Type (2015-2020)
Table 26. Global PCSK9 Inhibitors Revenue by Type (2015-2020) (US$ Million)
Table 27. Global PCSK9 Inhibitors Revenue Share by Type (2015-2020)
Table 28. PCSK9 Inhibitors Average Selling Price (ASP) by Type 2015-2020 (USD/Unit)
Table 29. Global PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 30. Global PCSK9 Inhibitors Sales Share by Application (2015-2020)
Table 31. North America PCSK9 Inhibitors Sales by Country (2015-2020) (K Units)
Table 32. North America PCSK9 Inhibitors Sales Market Share by Country (2015-2020)
Table 33. North America PCSK9 Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 34. North America PCSK9 Inhibitors Revenue Market Share by Country (2015-2020)
Table 35. North America PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 36. North America PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Table 37. North America PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 38. North America PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Table 39. Europe PCSK9 Inhibitors Sales by Country (2015-2020) (K Units)
Table 40. Europe PCSK9 Inhibitors Sales Market Share by Country (2015-2020)
Table 41. Europe PCSK9 Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 42. Europe PCSK9 Inhibitors Revenue Market Share by Country (2015-2020)
Table 43. Europe PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 44. Europe PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Table 45. Europe PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 46. Europe PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Table 47. Asia Pacific PCSK9 Inhibitors Sales by Region (2015-2020) (K Units)
Table 48. Asia Pacific PCSK9 Inhibitors Sales Market Share by Region (2015-2020)
Table 49. Asia Pacific PCSK9 Inhibitors Revenue by Region (2015-2020) (US$ Million)
Table 50. Asia Pacific PCSK9 Inhibitors Revenue Market Share by Region (2015-2020)
Table 51. Asia Pacific PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 52. Asia Pacific PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Table 53. Asia Pacific PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 54. Asia Pacific PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Table 55. Latin America PCSK9 Inhibitors Sales by Country (2015-2020) (K Units)
Table 56. Latin America PCSK9 Inhibitors Sales Market Share by Country (2015-2020)
Table 57. Latin Americaa PCSK9 Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 58. Latin America PCSK9 Inhibitors Revenue Market Share by Country (2015-2020)
Table 59. Latin America PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 60. Latin America PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Table 61. Latin America PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 62. Latin America PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Table 63. Middle East and Africa PCSK9 Inhibitors Sales by Country (2015-2020) (K Units)
Table 64. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country (2015-2020)
Table 65. Middle East and Africa PCSK9 Inhibitors Revenue by Country (2015-2020) (US$ Million)
Table 66. Middle East and Africa PCSK9 Inhibitors Revenue Market Share by Country (2015-2020)
Table 67. Middle East and Africa PCSK9 Inhibitors Sales by Type (2015-2020) (K Units)
Table 68. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Table 69. Middle East and Africa PCSK9 Inhibitors Sales by Application (2015-2020) (K Units)
Table 70. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Table 71. Amgen Corporation Information
Table 72. Amgen Description and Major Businesses
Table 73. Amgen PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 74. Amgen Product
Table 75. Amgen Recent Development
Table 76. Eli Lilly Corporation Information
Table 77. Eli Lilly Description and Major Businesses
Table 78. Eli Lilly PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 79. Eli Lilly Product
Table 80. Eli Lilly Recent Development
Table 81. Sanofi Corporation Information
Table 82. Sanofi Description and Major Businesses
Table 83. Sanofi PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 84. Sanofi Product
Table 85. Sanofi Recent Development
Table 86. Pfizer Corporation Information
Table 87. Pfizer Description and Major Businesses
Table 88. Pfizer PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 89. Pfizer Product
Table 90. Pfizer Recent Development
Table 91. Novartis Corporation Information
Table 92. Novartis Description and Major Businesses
Table 93. Novartis PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 94. Novartis Product
Table 95. Novartis Recent Development
Table 96. Roche Corporation Information
Table 97. Roche Description and Major Businesses
Table 98. Roche PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 99. Roche Product
Table 100. Roche Recent Development
Table 101. Merck Corporation Information
Table 102. Merck Description and Major Businesses
Table 103. Merck PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 104. Merck Product
Table 105. Merck Recent Development
Table 106. Alnylam Corporation Information
Table 107. Alnylam Description and Major Businesses
Table 108. Alnylam PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 109. Alnylam Product
Table 110. Alnylam Recent Development
Table 111. AstraZeneca Corporation Information
Table 112. AstraZeneca Description and Major Businesses
Table 113. AstraZeneca PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 114. AstraZeneca Product
Table 115. AstraZeneca Recent Development
Table 116. Affiris Corporation Information
Table 117. Affiris Description and Major Businesses
Table 118. Affiris PCSK9 Inhibitors Production (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 119. Affiris Product
Table 120. Affiris Recent Development
Table 121. BMS Corporation Information
Table 122. BMS Description and Major Businesses
Table 123. BMS PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 124. BMS Product
Table 125. BMS Recent Development
Table 126. Ionis Pharmaceuticals Corporation Information
Table 127. Ionis Pharmaceuticals Description and Major Businesses
Table 128. Ionis Pharmaceuticals PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 129. Ionis Pharmaceuticals Product
Table 130. Ionis Pharmaceuticals Recent Development
Table 131. Cyon Therapeutics Corporation Information
Table 132. Cyon Therapeutics Description and Major Businesses
Table 133. Cyon Therapeutics PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 134. Cyon Therapeutics Product
Table 135. Cyon Therapeutics Recent Development
Table 136. Daiichi Sankyo Corporation Information
Table 137. Daiichi Sankyo Description and Major Businesses
Table 138. Daiichi Sankyo PCSK9 Inhibitors Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2015-2020)
Table 139. Daiichi Sankyo Product
Table 140. Daiichi Sankyo Recent Development
Table 141. Global PCSK9 Inhibitors Sales Forecast by Regions (2021-2026) (K Units)
Table 142. Global PCSK9 Inhibitors Sales Market Share Forecast by Regions (2021-2026)
Table 143. Global PCSK9 Inhibitors Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 144. Global PCSK9 Inhibitors Revenue Market Share Forecast by Regions (2021-2026)
Table 145. North America: PCSK9 Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 146. North America: PCSK9 Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 147. Europe: PCSK9 Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 148. Europe: PCSK9 Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 149. Asia Pacific: PCSK9 Inhibitors Sales Forecast by Region (2021-2026) (K Units)
Table 150. Asia Pacific: PCSK9 Inhibitors Revenue Forecast by Region (2021-2026) (US$ Million)
Table 151. Latin America: PCSK9 Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 152. Latin America: PCSK9 Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 153. Middle East and Africa: PCSK9 Inhibitors Sales Forecast by Country (2021-2026) (K Units)
Table 154. Middle East and Africa: PCSK9 Inhibitors Revenue Forecast by Country (2021-2026) (US$ Million)
Table 155. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 156. Key Challenges
Table 157. Market Risks
Table 158. Main Points Interviewed from Key PCSK9 Inhibitors Players
Table 159. PCSK9 Inhibitors Customers List
Table 160. PCSK9 Inhibitors Distributors List
Table 161. Research Programs/Design for This Report
Table 162. Key Data Information from Secondary Sources
Table 163. Key Data Information from Primary Sources
List of Figures
Figure 1. PCSK9 Inhibitors Product Picture
Figure 2. Global PCSK9 Inhibitors Sales Market Share by Type in 2020 & 2026
Figure 3. Epatha（Evolocumab） Product Picture
Figure 4. Praluent（Alirocumab） Product Picture
Figure 5. Bococizumab Product Picture
Figure 6. Others Product Picture
Figure 7. Global PCSK9 Inhibitors Sales Market Share by Application in 2020 & 2026
Figure 8. Clinical Application
Figure 9. Drug Development
Figure 10. Other
Figure 11. PCSK9 Inhibitors Report Years Considered
Figure 12. Global PCSK9 Inhibitors Market Size 2015-2026 (US$ Million)
Figure 13. Global PCSK9 Inhibitors Sales 2015-2026 (K Units)
Figure 14. Global PCSK9 Inhibitors Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Global PCSK9 Inhibitors Sales Market Share by Region (2015-2020)
Figure 16. Global PCSK9 Inhibitors Sales Market Share by Region in 2019
Figure 17. Global PCSK9 Inhibitors Revenue Market Share by Region (2015-2020)
Figure 18. Global PCSK9 Inhibitors Revenue Market Share by Region in 2019
Figure 19. Global PCSK9 Inhibitors Sales Share by Manufacturer in 2019
Figure 20. The Top 10 and 5 Players Market Share by PCSK9 Inhibitors Revenue in 2019
Figure 21. PCSK9 Inhibitors Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 22. Global PCSK9 Inhibitors Sales Market Share by Type (2015-2020)
Figure 23. Global PCSK9 Inhibitors Sales Market Share by Type in 2019
Figure 24. Global PCSK9 Inhibitors Revenue Market Share by Type (2015-2020)
Figure 25. Global PCSK9 Inhibitors Revenue Market Share by Type in 2019
Figure 26. Global PCSK9 Inhibitors Market Share by Price Range (2015-2020)
Figure 27. Global PCSK9 Inhibitors Sales Market Share by Application (2015-2020)
Figure 28. Global PCSK9 Inhibitors Sales Market Share by Application in 2019
Figure 29. Global PCSK9 Inhibitors Revenue Market Share by Application (2015-2020)
Figure 30. Global PCSK9 Inhibitors Revenue Market Share by Application in 2019
Figure 31. North America PCSK9 Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 32. North America PCSK9 Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 33. North America PCSK9 Inhibitors Sales Market Share by Country in 2019
Figure 34. North America PCSK9 Inhibitors Revenue Market Share by Country in 2019
Figure 35. U.S. PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 36. U.S. PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Canada PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 38. Canada PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. North America PCSK9 Inhibitors Market Share by Type in 2019
Figure 40. North America PCSK9 Inhibitors Market Share by Application in 2019
Figure 41. Europe PCSK9 Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 42. Europe PCSK9 Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 43. Europe PCSK9 Inhibitors Sales Market Share by Country in 2019
Figure 44. Europe PCSK9 Inhibitors Revenue Market Share by Country in 2019
Figure 45. Germany PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 46. Germany PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. France PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 48. France PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. U.K. PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 50. U.K. PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Italy PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 52. Italy PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Russia PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 54. Russia PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Europe PCSK9 Inhibitors Market Share by Type in 2019
Figure 56. Europe PCSK9 Inhibitors Market Share by Application in 2019
Figure 57. Asia Pacific PCSK9 Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 58. Asia Pacific PCSK9 Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 59. Asia Pacific PCSK9 Inhibitors Sales Market Share by Region in 2019
Figure 60. Asia Pacific PCSK9 Inhibitors Revenue Market Share by Region in 2019
Figure 61. China PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 62. China PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Japan PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 64. Japan PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. South Korea PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 66. South Korea PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. India PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 68. India PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Australia PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 70. Australia PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Taiwan PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 72. Taiwan PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Indonesia PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 74. Indonesia PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Thailand PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 76. Thailand PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Malaysia PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 78. Malaysia PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Philippines PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 80. Philippines PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Vietnam PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 82. Vietnam PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Asia Pacific PCSK9 Inhibitors Market Share by Type in 2019
Figure 84. Asia Pacific PCSK9 Inhibitors Market Share by Application in 2019
Figure 85. Latin America PCSK9 Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 86. Latin America PCSK9 Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 87. Latin America PCSK9 Inhibitors Sales Market Share by Country in 2019
Figure 88. Latin America PCSK9 Inhibitors Revenue Market Share by Country in 2019
Figure 89. Mexico PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 90. Mexico PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 91. Brazil PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 92. Brazil PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Argentina PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 94. Argentina PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Latin America PCSK9 Inhibitors Market Share by Type in 2019
Figure 96. Latin America PCSK9 Inhibitors Market Share by Application in 2019
Figure 97. Middle East and Africa PCSK9 Inhibitors Sales Growth Rate 2015-2020 (K Units)
Figure 98. Middle East and Africa PCSK9 Inhibitors Revenue Growth Rate 2015-2020 (US$ Million)
Figure 99. Middle East and Africa PCSK9 Inhibitors Sales Market Share by Country in 2019
Figure 100. Middle East and Africa PCSK9 Inhibitors Revenue Market Share by Country in 2019
Figure 101. Turkey PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 102. Turkey PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 103. Saudi Arabia PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 104. Saudi Arabia PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. U.A.E PCSK9 Inhibitors Sales Growth Rate (2015-2020) (K Units)
Figure 106. U.A.E PCSK9 Inhibitors Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. Middle East and Africa PCSK9 Inhibitors Market Share by Type in 2019
Figure 108. Middle East and Africa PCSK9 Inhibitors Market Share by Application in 2019
Figure 109. North America PCSK9 Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 110. North America PCSK9 Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 111. Europe PCSK9 Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 112. Europe PCSK9 Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Asia Pacific PCSK9 Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 114. Asia Pacific PCSK9 Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Latin America PCSK9 Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 116. Latin America PCSK9 Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Middle East and Africa PCSK9 Inhibitors Sales Growth Rate Forecast (2021-2026) (K Units)
Figure 118. Middle East and Africa PCSK9 Inhibitors Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Porter's Five Forces Analysis
Figure 120. Channels of Distribution
Figure 121. Distributors Profiles
Figure 122. Bottom-up and Top-down Approaches for This Report
Figure 123. Data Triangulation
Figure 124. Key Executives Interviewed
TNF阻害剤の世界市場（～2026年） TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflamm…- シグナル伝達阻害剤の世界市場（～2026年） Signal transduction inhibitors are drugs that may prevent the ability of cancer cells to multiply quickly and invade other tissues. Growing need for effective cancer diagnostics and innovative therapies for cancer treatment are expected to be the major factors driving the signal transduction inhibit…
- DPP IV阻害剤（DPP-4阻害剤）の世界市場（～2026年） DPP IV inhibitors are a class of hypoglycemic agents that block the enzyme named dipeptidyl peptidase IV. Dipeptidyl peptidase IV enzyme break down the proteins that are responsible for stimulating the insulin producing cells that slows down gastric secretion. Proteins can activate the release of in…
- プロテアソーム阻害剤の世界市場（～2026年） Proteasome inhibitors are drugs that block the action of proteasomes, cellular complexes that break down proteins. Proteasome inhibitors are being studied in the treatment of cancer and are used in treating multiple myeloma. Market Analysis and Insights: Global Proteasome Inhibitors Market The globa…
- 重合阻害剤の世界市場（～2026年） Monomers are often stabilized by the addition of inhibitors to prevent polymerization initiation by light, heat and air. Asia Pacific is estimated to be the fastest growing region in the global polymerization inhibitors market owing to increasing demand for it. Market Analysis and Insights: Global P…